An observational study in Breast Cancer, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Breast Neoplasms by Duke University — 8 open to participants now, 10 under way, none of them phase 3. Breast Neoplasms · Duke University.
Among the 69 studies in Breast Neoplasms by Duke University, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2026, is one of 10 observational ones, and was the 69th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →8 of the 69 studies in Breast Neoplasms by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18+ · Women only
Duke University · Sites in United States
Ages 21–90 · Women only
Duke University · Sites in United States
Ages 18+ · Women only
Duke University · Sites in United States
Ages 18–39
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13
First in 1997; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 40 across the 58 interventional studies, 61 across the 10 observational. Of the 55 that completed or were terminated, 12 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
3 of the studies in Breast Neoplasms by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07426952Duke UniversityWeight Management After Cancer for Survivors in Rural Communities | 2026-12-31 |
| NCT06983691Duke UniversityPatient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib | 2027-03 |
| NCT06658912Duke UniversityPlanning Grant for TOPS for Breast Cancer Survivors | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 69 studies in Breast Neoplasms by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Breast cancer treatment sometimes includes radiation to the breast or chest wall. There is a small gland, called the thymus, located in the upper chest that may receive a small amount of the radiation aimed at the breast. The goal of this study is to collect blood samples from young women with breast cancer to study the effect of radiation therapy on the thymus gland.
This study includes participants whose plan of care may or may not include radiation therapy.
Participants whose plan of care includes radiation therapy will have about three teaspoons of research blood collected at the following time points:
Participants whose plan of care does NOT include radiation therapy will have about three teaspoons of research blood collected at the following timepoints:
The study population includes women age 18-50 with breast cancer seen in the Duke Breast Oncology Program
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 100 Breast cancer patients receiving radiation therapy
Procedure: Blood draw for the laboratory assessment
Up to 25 Breast cancer patients NOT receiving radiation therapy as control
Procedure: Blood draw for the laboratory assessment
Blood will be drawn and processed for Peripheral Blood Mononuclear Cells (PBMCs). PBMC biomarkers will be used to assess thymopoiesis .
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
As measured by quantitative PCR in participants receiving radiotherapy (RT)
Time frame: baseline
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
As measured by quantitative PCR in participants receiving radiotherapy (RT)
Time frame: at the end of RT, about 5 weeks
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
As measured by quantitative PCR in participants receiving radiotherapy (RT)
Time frame: 6 months post-RT
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
As measured by quantitative PCR in participants NOT receiving radiotherapy (RT)
Time frame: within 3 months after breast cancer surgery
Level of signal joint T cell Receptor Exclusion Circles (sjTREC) in peripheral blood T cells
As measured by quantitative PCR in participants NOT receiving radiotherapy (RT)
Time frame: approximately 8-11 months after breast cancer surgery
Level of CD4+ recent thymic emigrant (RTE) cells in participant blood samples
As measured by flow cytometry in blood from participants receiving radiotherapy (RT)
Time frame: baseline
Level of CD4+ RTE cells in participant blood samples
As measured by flow cytometry in blood from participants receiving radiotherapy (RT)
Time frame: at the end of RT, about 5 weeks
Level of CD4+ RTE cells in participant blood samples
As measured by flow cytometry in blood from participants receiving radiotherapy (RT)
Time frame: 6 months post RT
Level of CD4+ RTE cells in participant blood samples
As measured by flow cytometry in blood from participants NOT receiving radiotherapy (RT)
Time frame: within 3 months of breast cancer surgery
Level of CD4+ RTE cells in participant blood samples
As measured by flow cytometry in blood from participants NOT receiving radiotherapy (RT)
Time frame: approximately 8-11 months after breast cancer surgery
Effect of adjuvant radiotherapy treatment dose on levels of sjTREC-containing T cells
using a linear mixed-effect model in participants receiving RT
Time frame: 6 months post RT
Effect of adjuvant radiotherapy treatment fractionation on levels of sjTREC-containing T cells
using a linear mixed-effect model in participants receiving RT
Time frame: 6 months post RT
Effect of adjuvant radiotherapy treatment fractionation on levels of CD4+ RTE cells
using a linear mixed-effect model in participants receiving RT
Time frame: 6 months post RT
Effect of adjuvant radiotherapy treatment dose on levels of CD4+ RTE cells
using a linear mixed-effect model in participants receiving RT
Time frame: 6 months post RT
Plan to share: Undecided — IPD may be shared after publication if deidentified.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2029, 36 months later.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 36 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Sep 2026 → Nov 2026, primary completion Sep 2029 → Nov 2029 and completion Sep 2029 → Nov 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.